Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 21, 2025PharmaceuticalsOpen Access

Molecular Basis of BRAF Inhibitor Resistance in Melanoma: A Systematic Review

View Full Paper
Ask AI
Bookmark
Share

Authors

ICIlaria CosciUniversity of PaduaVSValentina SalizzatoIstituto Oncologico VenetoPFPaolo Del FioreIstituto Oncologico Veneto

Discussion

Loading...

Member takes

Implication

Systematic review reveals resistance mechanisms to BRAF-targeted therapies in melanoma, highlighting adaptive and acquired resistance forms.

Key Points

  • Resistance mechanisms to BRAF inhibitors include primary, adaptive, and acquired forms in melanoma therapies.
  • High-throughput sequencing identified mutations like NRAS and PTEN that drive resistance in melanoma patients.
  • Molecular alterations in signaling pathways, including PI3K-AKT, contribute to therapy resistance challenges.
  • Adopting combinatorial therapies and precision oncology strategies may enhance treatment outcomes in advanced melanoma.

Cite This Study

Cosci et al. (2025) studied this question.

synapsesocial.com/papers/68af75207567bf4f94feea47https://doi.org/10.3390/ph18081235
View Full Paper
Ask AI
Bookmark
Share